- Home
- REGN vs JCI Comparison
REGN vs JCI Comparison
Compare REGN & JCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- JCI
- Stock Information
- Founded
- REGN 1988
- JCI 1885
- Country
- REGN United States
- JCI Ireland
- Employees
- REGN N/A
- JCI N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- JCI Industrial Machinery/Components
- Sector
- REGN Health Care
- JCI Industrials
- Exchange
- REGN Nasdaq
- JCI Nasdaq
- Market Cap
- REGN 63.4B
- JCI 55.0B
- IPO Year
- REGN 1991
- JCI N/A
- Fundamental
- Price
- REGN $563.16
- JCI $76.83
- Analyst Decision
- REGN Buy
- JCI Buy
- Analyst Count
- REGN 23
- JCI 14
- Target Price
- REGN $971.57
- JCI $88.29
- AVG Volume (30 Days)
- REGN 1.1M
- JCI 4.9M
- Earning Date
- REGN 04-29-2025
- JCI 05-07-2025
- Dividend Yield
- REGN 0.16%
- JCI 1.88%
- EPS Growth
- REGN 10.27
- JCI N/A
- EPS
- REGN 38.34
- JCI 2.61
- Revenue
- REGN $14,202,000,000.00
- JCI $23,169,000,000.00
- Revenue This Year
- REGN $4.06
- JCI $2.90
- Revenue Next Year
- REGN $6.54
- JCI $4.72
- P/E Ratio
- REGN $14.69
- JCI $36.07
- Revenue Growth
- REGN 8.27
- JCI 7.90
- 52 Week Low
- REGN $525.99
- JCI $59.83
- 52 Week High
- REGN $1,211.20
- JCI $91.14
- Technical
- Relative Strength Index (RSI)
- REGN 37.15
- JCI 45.50
- Support Level
- REGN $544.50
- JCI $75.91
- Resistance Level
- REGN $575.20
- JCI $79.84
- Average True Range (ATR)
- REGN 28.44
- JCI 3.51
- MACD
- REGN -1.59
- JCI 0.11
- Stochastic Oscillator
- REGN 32.25
- JCI 58.55
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.